Loading…

Immunological Effects of Integrase Inhibitors versus Protease and Non-Nucleoside Reverse Transcriptase Inhibitors as Part of Initial Therapy in People Living with HIV. A Systematic Review

Introduction: The use of integrase inhibitors within highly active antiretroviral therapy (HAART) has demonstrated benefits for individuals living with HIV. However, most comparisons are based on effectiveness against viral replication, with limited information on their impact on the immune system....

Full description

Saved in:
Bibliographic Details
Published in:Iatreia (Medellín, Colombia) Colombia), 2024-07, Vol.37 (3), p.354-366
Main Authors: Melissa Gutiérrez-Gómez, Sofía Giraldo-Hoyos, Salomón Gallego-Quintero, Natalia Taborda-Vanegas, María Teresa Rugeles-López, Juan Carlos Alzate-Ángel
Format: Article
Language:Spanish
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 366
container_issue 3
container_start_page 354
container_title Iatreia (Medellín, Colombia)
container_volume 37
creator Melissa Gutiérrez-Gómez
Sofía Giraldo-Hoyos
Salomón Gallego-Quintero
Natalia Taborda-Vanegas
María Teresa Rugeles-López
Juan Carlos Alzate-Ángel
description Introduction: The use of integrase inhibitors within highly active antiretroviral therapy (HAART) has demonstrated benefits for individuals living with HIV. However, most comparisons are based on effectiveness against viral replication, with limited information on their impact on the immune system. Objective: To identify immunological outcomes in studies comparing in- tegrase inhibitors (INSTIs) with other drugs used as third agents in HAART. Methods: Systematic review of studies reporting patients treated with INS- TIs versus non-nucleoside reverse transcriptase inhibitors (NNRTIs) or pro-tease inhibitors (PIs) as the third drug in HAART. Immunological reconstitution outcomes were assessed, including CD4+ T lymphocyte count, CD4/ CD8 ratio, serum concentration of sCD14, D-dimer, and C-reactive protein, as well as the frequency and phenotype of T cells, functional capacity of T cells, and proviral DNA. Results: A total of 2804 studies were screened, 59 were evaluated in full text and four were included in the synthesis. A cohort study reported normalization of the CD4/CD8 ratio in patients initiating treatment with INSTIs compared to PIs or NNRTIs. However, this finding was not consistently replicated in other studies, and in one of them, this ratio was higher in those receiving efavirenz vs. dolutegravir. No evidence was found for other outcomes. Conclusions: The analyzed studies are inconclusive regarding differences in immunological reconstitution between INSTIs vs. PIs and NNRTIs.
doi_str_mv 10.17533/udea.iatreia.255
format article
fullrecord <record><control><sourceid>doaj</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_22bc1481d4b94a9693e9786b39718929</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_22bc1481d4b94a9693e9786b39718929</doaj_id><sourcerecordid>oai_doaj_org_article_22bc1481d4b94a9693e9786b39718929</sourcerecordid><originalsourceid>FETCH-doaj_primary_oai_doaj_org_article_22bc1481d4b94a9693e9786b397189293</originalsourceid><addsrcrecordid>eNqtjk1Ow0AMhUcIJMrPAdj5AgmZ_DSdJUJFjYSqCiq2kZM4qaskE81MWvVsXI4UWLFm5Se_5_dZiAcZ-DJNouhxrAh9RmeI0Q-T5ELMwkBKL1Xz5FLMAhlKL0hVdC1urN0HQaKiIJ6Jz6zrxl63uuESW1jWNZXOgq4h6x01Bi1NascFO20sHMjY0cLGaEdnC_sK1rr31mPZkrZcEbzROUSwNdjb0vDg_nTgdI_G_TDY8YTd7sjgcALuYUN6aAle-cB9A0d2O1hlHz48wfvJOurQcXlmMB3vxFWNraX733krspfl9nnlVRr3-WC4Q3PKNXL-vdCmyScuT5_mYViUMl7IKi5UjGquIlLpYl5EKpULFaroP7u-ADjch0g</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Immunological Effects of Integrase Inhibitors versus Protease and Non-Nucleoside Reverse Transcriptase Inhibitors as Part of Initial Therapy in People Living with HIV. A Systematic Review</title><source>Publicly Available Content Database</source><creator>Melissa Gutiérrez-Gómez ; Sofía Giraldo-Hoyos ; Salomón Gallego-Quintero ; Natalia Taborda-Vanegas ; María Teresa Rugeles-López ; Juan Carlos Alzate-Ángel</creator><creatorcontrib>Melissa Gutiérrez-Gómez ; Sofía Giraldo-Hoyos ; Salomón Gallego-Quintero ; Natalia Taborda-Vanegas ; María Teresa Rugeles-López ; Juan Carlos Alzate-Ángel</creatorcontrib><description>Introduction: The use of integrase inhibitors within highly active antiretroviral therapy (HAART) has demonstrated benefits for individuals living with HIV. However, most comparisons are based on effectiveness against viral replication, with limited information on their impact on the immune system. Objective: To identify immunological outcomes in studies comparing in- tegrase inhibitors (INSTIs) with other drugs used as third agents in HAART. Methods: Systematic review of studies reporting patients treated with INS- TIs versus non-nucleoside reverse transcriptase inhibitors (NNRTIs) or pro-tease inhibitors (PIs) as the third drug in HAART. Immunological reconstitution outcomes were assessed, including CD4+ T lymphocyte count, CD4/ CD8 ratio, serum concentration of sCD14, D-dimer, and C-reactive protein, as well as the frequency and phenotype of T cells, functional capacity of T cells, and proviral DNA. Results: A total of 2804 studies were screened, 59 were evaluated in full text and four were included in the synthesis. A cohort study reported normalization of the CD4/CD8 ratio in patients initiating treatment with INSTIs compared to PIs or NNRTIs. However, this finding was not consistently replicated in other studies, and in one of them, this ratio was higher in those receiving efavirenz vs. dolutegravir. No evidence was found for other outcomes. Conclusions: The analyzed studies are inconclusive regarding differences in immunological reconstitution between INSTIs vs. PIs and NNRTIs.</description><identifier>ISSN: 0121-0793</identifier><identifier>EISSN: 2011-7965</identifier><identifier>DOI: 10.17533/udea.iatreia.255</identifier><language>spa</language><publisher>Universidad de Antioquia</publisher><subject>antiretroviral therapy ; highly active ; hiv integrase inhibitors ; immune reconstitution ; systematic review</subject><ispartof>Iatreia (Medellín, Colombia), 2024-07, Vol.37 (3), p.354-366</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0001-7855-1409 ; 0000-0002-1609-2873 ; 0000-0003-0319-0623 ; 0000-0001-6085-855X ; 0000-0001-7384-9599 ; 0000-0001-7293-1427</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Melissa Gutiérrez-Gómez</creatorcontrib><creatorcontrib>Sofía Giraldo-Hoyos</creatorcontrib><creatorcontrib>Salomón Gallego-Quintero</creatorcontrib><creatorcontrib>Natalia Taborda-Vanegas</creatorcontrib><creatorcontrib>María Teresa Rugeles-López</creatorcontrib><creatorcontrib>Juan Carlos Alzate-Ángel</creatorcontrib><title>Immunological Effects of Integrase Inhibitors versus Protease and Non-Nucleoside Reverse Transcriptase Inhibitors as Part of Initial Therapy in People Living with HIV. A Systematic Review</title><title>Iatreia (Medellín, Colombia)</title><description>Introduction: The use of integrase inhibitors within highly active antiretroviral therapy (HAART) has demonstrated benefits for individuals living with HIV. However, most comparisons are based on effectiveness against viral replication, with limited information on their impact on the immune system. Objective: To identify immunological outcomes in studies comparing in- tegrase inhibitors (INSTIs) with other drugs used as third agents in HAART. Methods: Systematic review of studies reporting patients treated with INS- TIs versus non-nucleoside reverse transcriptase inhibitors (NNRTIs) or pro-tease inhibitors (PIs) as the third drug in HAART. Immunological reconstitution outcomes were assessed, including CD4+ T lymphocyte count, CD4/ CD8 ratio, serum concentration of sCD14, D-dimer, and C-reactive protein, as well as the frequency and phenotype of T cells, functional capacity of T cells, and proviral DNA. Results: A total of 2804 studies were screened, 59 were evaluated in full text and four were included in the synthesis. A cohort study reported normalization of the CD4/CD8 ratio in patients initiating treatment with INSTIs compared to PIs or NNRTIs. However, this finding was not consistently replicated in other studies, and in one of them, this ratio was higher in those receiving efavirenz vs. dolutegravir. No evidence was found for other outcomes. Conclusions: The analyzed studies are inconclusive regarding differences in immunological reconstitution between INSTIs vs. PIs and NNRTIs.</description><subject>antiretroviral therapy</subject><subject>highly active</subject><subject>hiv integrase inhibitors</subject><subject>immune reconstitution</subject><subject>systematic review</subject><issn>0121-0793</issn><issn>2011-7965</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNqtjk1Ow0AMhUcIJMrPAdj5AgmZ_DSdJUJFjYSqCiq2kZM4qaskE81MWvVsXI4UWLFm5Se_5_dZiAcZ-DJNouhxrAh9RmeI0Q-T5ELMwkBKL1Xz5FLMAhlKL0hVdC1urN0HQaKiIJ6Jz6zrxl63uuESW1jWNZXOgq4h6x01Bi1NascFO20sHMjY0cLGaEdnC_sK1rr31mPZkrZcEbzROUSwNdjb0vDg_nTgdI_G_TDY8YTd7sjgcALuYUN6aAle-cB9A0d2O1hlHz48wfvJOurQcXlmMB3vxFWNraX733krspfl9nnlVRr3-WC4Q3PKNXL-vdCmyScuT5_mYViUMl7IKi5UjGquIlLpYl5EKpULFaroP7u-ADjch0g</recordid><startdate>20240701</startdate><enddate>20240701</enddate><creator>Melissa Gutiérrez-Gómez</creator><creator>Sofía Giraldo-Hoyos</creator><creator>Salomón Gallego-Quintero</creator><creator>Natalia Taborda-Vanegas</creator><creator>María Teresa Rugeles-López</creator><creator>Juan Carlos Alzate-Ángel</creator><general>Universidad de Antioquia</general><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-7855-1409</orcidid><orcidid>https://orcid.org/0000-0002-1609-2873</orcidid><orcidid>https://orcid.org/0000-0003-0319-0623</orcidid><orcidid>https://orcid.org/0000-0001-6085-855X</orcidid><orcidid>https://orcid.org/0000-0001-7384-9599</orcidid><orcidid>https://orcid.org/0000-0001-7293-1427</orcidid></search><sort><creationdate>20240701</creationdate><title>Immunological Effects of Integrase Inhibitors versus Protease and Non-Nucleoside Reverse Transcriptase Inhibitors as Part of Initial Therapy in People Living with HIV. A Systematic Review</title><author>Melissa Gutiérrez-Gómez ; Sofía Giraldo-Hoyos ; Salomón Gallego-Quintero ; Natalia Taborda-Vanegas ; María Teresa Rugeles-López ; Juan Carlos Alzate-Ángel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-doaj_primary_oai_doaj_org_article_22bc1481d4b94a9693e9786b397189293</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>spa</language><creationdate>2024</creationdate><topic>antiretroviral therapy</topic><topic>highly active</topic><topic>hiv integrase inhibitors</topic><topic>immune reconstitution</topic><topic>systematic review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Melissa Gutiérrez-Gómez</creatorcontrib><creatorcontrib>Sofía Giraldo-Hoyos</creatorcontrib><creatorcontrib>Salomón Gallego-Quintero</creatorcontrib><creatorcontrib>Natalia Taborda-Vanegas</creatorcontrib><creatorcontrib>María Teresa Rugeles-López</creatorcontrib><creatorcontrib>Juan Carlos Alzate-Ángel</creatorcontrib><collection>Directory of Open Access Journals</collection><jtitle>Iatreia (Medellín, Colombia)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Melissa Gutiérrez-Gómez</au><au>Sofía Giraldo-Hoyos</au><au>Salomón Gallego-Quintero</au><au>Natalia Taborda-Vanegas</au><au>María Teresa Rugeles-López</au><au>Juan Carlos Alzate-Ángel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunological Effects of Integrase Inhibitors versus Protease and Non-Nucleoside Reverse Transcriptase Inhibitors as Part of Initial Therapy in People Living with HIV. A Systematic Review</atitle><jtitle>Iatreia (Medellín, Colombia)</jtitle><date>2024-07-01</date><risdate>2024</risdate><volume>37</volume><issue>3</issue><spage>354</spage><epage>366</epage><pages>354-366</pages><issn>0121-0793</issn><eissn>2011-7965</eissn><abstract>Introduction: The use of integrase inhibitors within highly active antiretroviral therapy (HAART) has demonstrated benefits for individuals living with HIV. However, most comparisons are based on effectiveness against viral replication, with limited information on their impact on the immune system. Objective: To identify immunological outcomes in studies comparing in- tegrase inhibitors (INSTIs) with other drugs used as third agents in HAART. Methods: Systematic review of studies reporting patients treated with INS- TIs versus non-nucleoside reverse transcriptase inhibitors (NNRTIs) or pro-tease inhibitors (PIs) as the third drug in HAART. Immunological reconstitution outcomes were assessed, including CD4+ T lymphocyte count, CD4/ CD8 ratio, serum concentration of sCD14, D-dimer, and C-reactive protein, as well as the frequency and phenotype of T cells, functional capacity of T cells, and proviral DNA. Results: A total of 2804 studies were screened, 59 were evaluated in full text and four were included in the synthesis. A cohort study reported normalization of the CD4/CD8 ratio in patients initiating treatment with INSTIs compared to PIs or NNRTIs. However, this finding was not consistently replicated in other studies, and in one of them, this ratio was higher in those receiving efavirenz vs. dolutegravir. No evidence was found for other outcomes. Conclusions: The analyzed studies are inconclusive regarding differences in immunological reconstitution between INSTIs vs. PIs and NNRTIs.</abstract><pub>Universidad de Antioquia</pub><doi>10.17533/udea.iatreia.255</doi><orcidid>https://orcid.org/0000-0001-7855-1409</orcidid><orcidid>https://orcid.org/0000-0002-1609-2873</orcidid><orcidid>https://orcid.org/0000-0003-0319-0623</orcidid><orcidid>https://orcid.org/0000-0001-6085-855X</orcidid><orcidid>https://orcid.org/0000-0001-7384-9599</orcidid><orcidid>https://orcid.org/0000-0001-7293-1427</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0121-0793
ispartof Iatreia (Medellín, Colombia), 2024-07, Vol.37 (3), p.354-366
issn 0121-0793
2011-7965
language spa
recordid cdi_doaj_primary_oai_doaj_org_article_22bc1481d4b94a9693e9786b39718929
source Publicly Available Content Database
subjects antiretroviral therapy
highly active
hiv integrase inhibitors
immune reconstitution
systematic review
title Immunological Effects of Integrase Inhibitors versus Protease and Non-Nucleoside Reverse Transcriptase Inhibitors as Part of Initial Therapy in People Living with HIV. A Systematic Review
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T01%3A14%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-doaj&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunological%20Effects%20of%20Integrase%20Inhibitors%20versus%20Protease%20and%20Non-Nucleoside%20Reverse%20Transcriptase%20Inhibitors%20as%20Part%20of%20Initial%20Therapy%20in%20People%20Living%20with%20HIV.%20A%20Systematic%20Review&rft.jtitle=Iatreia%20(Medelli%CC%81n,%20Colombia)&rft.au=Melissa%20Guti%C3%A9rrez-G%C3%B3mez&rft.date=2024-07-01&rft.volume=37&rft.issue=3&rft.spage=354&rft.epage=366&rft.pages=354-366&rft.issn=0121-0793&rft.eissn=2011-7965&rft_id=info:doi/10.17533/udea.iatreia.255&rft_dat=%3Cdoaj%3Eoai_doaj_org_article_22bc1481d4b94a9693e9786b39718929%3C/doaj%3E%3Cgrp_id%3Ecdi_FETCH-doaj_primary_oai_doaj_org_article_22bc1481d4b94a9693e9786b397189293%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true